Cartesian Therapeutics (RNAC) Receivables - Net (2016 - 2026)

Cartesian Therapeutics (RNAC) has disclosed Receivables - Net for 12 consecutive years, with $261000.0 as the latest value for Q1 2026.

  • For Q1 2026, Receivables - Net fell 85.21% year-over-year to $261000.0; the TTM value through Mar 2026 reached $261000.0, down 85.21%, while the annual FY2025 figure was $1.1 million, 27.87% up from the prior year.
  • Receivables - Net hit $261000.0 in Q1 2026 for Cartesian Therapeutics, down from $1.1 million in the prior quarter.
  • Across five years, Receivables - Net topped out at $32.0 million in Q2 2024 and bottomed at $261000.0 in Q1 2026.
  • Average Receivables - Net over 5 years is $6.6 million, with a median of $4.9 million recorded in 2023.
  • Year-over-year, Receivables - Net soared 494.97% in 2024 and then plummeted 98.9% in 2025.
  • Cartesian Therapeutics' Receivables - Net stood at $6.6 million in 2022, then decreased by 11.01% to $5.9 million in 2023, then tumbled by 85.14% to $872000.0 in 2024, then grew by 27.87% to $1.1 million in 2025, then plummeted by 76.59% to $261000.0 in 2026.
  • According to Business Quant data, Receivables - Net over the past three periods came in at $261000.0, $1.1 million, and $722000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.